Review of Targeted Therapy in Chronic Lymphocytic Leukemia: What a Radiologist Needs to Know About CT Interpretation

Overview

Journal Cancer Imaging

Publisher Springer Nature

Specialties Oncology
Radiology

Date 2018 Apr 20

PMID 29669600

Citations 1

Authors

Babina Gosangi

Matthew Davids

Bhanusupriya Somarouthu

Francesco Alessandrino

Angela Giardino

Nikhil Ramaiya

Katherine Krajewski

Affiliations

Soon will be listed here.

Abstract

The last 5 years have been marked by profound innovation in the targeted treatment of chronic lymphocytic leukemia (CLL) and indolent lymphomas. Using CLL as a case study, we present a timeline and overview of the current treatment landscape for the radiologist, including an overview of clinical and radiological features of CLL, discussion of the targeted agents themselves, and the role of imaging in response and toxicity assessment. The goal is to familiarize the radiologist with multiple Food and Drug Administration (FDA)-approved targeted agents used in this setting and associated adverse events which are commonly observed in this patient population.

Citing Articles

Blood and Guts: Diarrhea from Colonic Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Zikos T, Triadafilopoulos G, Berube C, Regalia K Dig Dis Sci. 2018; 64(2):345-348.

PMID: 30155841 DOI: 10.1007/s10620-018-5264-4.

References

Coutre S, Barrientos J, Brown J, de Vos S, Furman R, Keating M . Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015; 56(10):2779-86. PMC: 4732460. DOI: 10.3109/10428194.2015.1022770. View

Falchi L, Keating M, Marom E, Truong M, Schlette E, Sargent R . Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014; 123(18):2783-90. PMC: 4123418. DOI: 10.1182/blood-2013-11-536169. View

Kakimoto T, Nakazato T, Hayashi R, Hayashi H, Hayashi N, Ishiyama T . Bilateral occipital lobe invasion in chronic lymphocytic leukemia. J Clin Oncol. 2009; 28(3):e30-2. DOI: 10.1200/JCO.2009.23.8436. View

Burger J, Tedeschi A, Barr P, Robak T, Owen C, Ghia P . Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 373(25):2425-37. PMC: 4722809. DOI: 10.1056/NEJMoa1509388. View

Haustraete E, Obert J, Diab S, Abbes S, Zini J, Valade S . Idelalisib-related pneumonitis. Eur Respir J. 2016; 47(4):1280-3. DOI: 10.1183/13993003.01670-2015. View

Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour J, Munir T . Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016; 17(6):768-778. DOI: 10.1016/S1470-2045(16)30019-5. View

Moon J, Kim E, Lee K, Kim T, Jung K, Song J . Cytomegalovirus pneumonia: high-resolution CT findings in ten non-AIDS immunocompromised patients. Korean J Radiol. 2001; 1(2):73-8. PMC: 2718167. DOI: 10.3348/kjr.2000.1.2.73. View

Barth M, Czuczman M . Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia. Future Oncol. 2013; 9(12):1829-39. DOI: 10.2217/fon.13.219. View

Demko S, Summers J, Keegan P, Pazdur R . FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Oncologist. 2008; 13(2):167-74. DOI: 10.1634/theoncologist.2007-0218. View

10.

Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner C . Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014; 370(12):1101-10. DOI: 10.1056/NEJMoa1313984. View

11.

Bollee G, Sarfati C, Thiery G, Bergeron A, de Miranda S, Menotti J . Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest. 2007; 132(4):1305-10. DOI: 10.1378/chest.07-0223. View

12.

Hillmen P, Skotnicki A, Robak T, Jaksic B, Dmoszynska A, Wu J . Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007; 25(35):5616-23. DOI: 10.1200/JCO.2007.12.9098. View

13.

Seiter K, Stiefel M, Barrientos J, Shaikh A, Ahmed N, Baskind P . Successful treatment of ibrutinib-associated central nervous system hemorrhage with platelet transfusion support. Stem Cell Investig. 2016; 3:27. PMC: 4981699. DOI: 10.21037/sci.2016.06.08. View

14.

Hallek M, Fischer K, Fingerle-Rowson G, Fink A, Busch R, Mayer J . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376(9747):1164-74. DOI: 10.1016/S0140-6736(10)61381-5. View

15.

Chen Q, Jain N, Ayer T, Wierda W, Flowers C, OBrien S . Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. J Clin Oncol. 2016; 35(2):166-174. PMC: 5559889. DOI: 10.1200/JCO.2016.68.2856. View

16.

Roberts A, Davids M, Pagel J, Kahl B, Puvvada S, Gerecitano J . Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 374(4):311-22. PMC: 7107002. DOI: 10.1056/NEJMoa1513257. View

17.

Burton C, Kaczmarski R, Jan-Mohamed R . Interstitial pneumonitis related to rituximab therapy. N Engl J Med. 2003; 348(26):2690-1; discussion 2690-1. DOI: 10.1056/NEJM200306263482619. View

18.

Damle R, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94(6):1840-7. View

19.

van Oers M, Kuliczkowski K, Smolej L, Petrini M, Offner F, Grosicki S . Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2015; 16(13):1370-9. DOI: 10.1016/S1470-2045(15)00143-6. View

20.

Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L . Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2001; 343(26):1910-6. DOI: 10.1056/NEJM200012283432602. View